Related Experiment Video
Updated: Jun 3, 2025
Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits
Published on: June 2, 2019
Angiopoietin-2: A Therapeutic Target for Vascular Protection in Hutchinson-Gilford Progeria Syndrome
1Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA.
Insights
Hutchinson-Gilford progeria syndrome (HGPS) involves toxic progerin protein accumulation, causing accelerated aging and cardiovascular issues. Angiopoietin-2 (Ang2) shows therapeutic potential for HGPS by addressing defective angiogenesis and vascular stability.
Area of Science:
- Cellular and Molecular Biology
- Pediatric Pathology
- Cardiovascular Research
Background:
- Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder mimicking accelerated aging.
- Accumulation of toxic progerin protein disrupts cellular functions, leading to severe health complications.
- Cardiovascular disease, particularly atherosclerosis, is the primary cause of mortality in HGPS patients.
Purpose of the Study:
- To review the clinical manifestations and cellular pathology of HGPS.
- To explore the role of defective angiogenesis in HGPS-related cardiovascular complications.
- To discuss the therapeutic potential of Angiopoietin-2 (Ang2) for HGPS treatment.
Main Methods:
- Literature review of HGPS pathogenesis and cardiovascular disease mechanisms.
- Analysis of cellular processes affected by progerin accumulation.
- Evaluation of Angiopoietin-2 (Ang2) as a potential therapeutic target.
Main Results:
- Progerin accumulation leads to cellular dysfunction and premature aging phenotypes.
- Defective angiogenesis is a critical factor in the development of atherosclerosis in HGPS.
- Angiopoietin-2 (Ang2) plays a key role in regulating angiogenesis and vascular stability.
Conclusions:
- Despite current treatments, cardiovascular complications remain a major challenge in HGPS.
- Targeting angiogenesis with Angiopoietin-2 (Ang2) may offer a novel therapeutic strategy for HGPS.
- Further research into Ang2's role in HGPS is warranted to develop effective treatments.
Abstract:
Hutchinson-Gilford progeria syndrome (HGPS) is a pediatric condition characterized by clinical features that resemble accelerated aging. The abnormal accumulation of a toxic form of the lamin A protein known as progerin disrupts cellular functions, leading to various complications, including growth retardation, loss of subcutaneous fat, abnormal skin, alopecia, osteoporosis, and progressive joint contractures. Death primarily occurs as the result of complications from progressive atherosclerosis, especially from cardiac disease, such as myocardial infarction or heart failure, or cerebrovascular disease like stroke. Despite the availability of lonafarnib, the only US Food and Drug Administration-approved treatment for HGPS, cardiovascular complications remain the leading cause of morbidity and mortality in affected patients. Defective angiogenesis-the process of forming new blood vessels from existing ones-plays a crucial role in the development of cardiovascular disease. A recent study suggests that Angiopoietin-2 (Ang2), a pro-angiogenic growth factor that regulates angiogenesis and vascular stability, may offer therapeutic potential for the treatment of HGPS. In this review, we describe the clinical features and key cellular processes impacted by progerin and discuss the therapeutic potential of Ang2 in addressing these challenges.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:22iPS Cell Differentiation
01:10Mechanism of Angiogenesis